Infect Chemother.  2012 Aug;44(4):328-330. 10.3947/ic.2012.44.4.328.

Epidemiology and Clinical Characteristics of Invasive Pulmonary Aspergillosis in Korea: Tasks for the Future

• Lee DG

• KMID: 2045557
• DOI: http://doi.org/10.3947/ic.2012.44.4.328

Abstract

Invasive pulmonary aspergillosis (IPA) is a leading cause of morbididy and mortality for patients with malignancy and transplantation recipients. Recent advances in diagnosis and treatment strategies can improve patients' survival. In addition, because the epidemiologies of invasive fungal infections would differ between Korea and Western countries, Organization of a nationwide network in collaboration with infectious diseases specialists, medical microbiologists, and government personnels is also anticipated. Due to a restricted reimbursement system in Korea, current clinical practices for treatment of IPA are limited. According to the textbooks and guidelines from results of well designed clinical trials and extensive clinical experiences, criteria for insurance benefits should be improved in the near future.

Keyword

Invasive pulmonary aspergillosis; Epidemiology; Insurance; Health; Reimbursement

MeSH Terms

Communicable Diseases
Cooperative Behavior
Humans
Insurance
Insurance Benefits
Invasive Pulmonary Aspergillosis
Korea
Specialization
Transplants

Reference

1. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Park SW, Choe YJ, Oh MD, Choe KW. Clinical manifestations and treatment outcome of invasive aspergillosis. Infect Chemother. 2002. 34:160–166.

2. Yoo JH, Choi JH, Lee DG, Choi S, Shin WS, Kim CC. Analysis of invasive fungal infection after hematopoietic stem cell transplanatation or chemotherapy in patients with hematologic diseases. Infect Chemother. 2004. 36:40–45.

3. Kim JM, Kwon CH, Joh JW, Song S, Shin M, Kim SJ, Hong SH, Kim BN, Lee SK. Aspergillosis in liver transplant recipients: a single center experience. J Korean Surg Soc. 2010. 79:267–274.

4. Kim SH, Moon SM, Han SH, Chung JW, Moon SY, Choo EJ, Choi YW, Kim SW, Bae IG, Kwon HH, Peck KR, Kim YS. Epidemiology and clinical outcomes of invasive pulmonary aspergillosis: a nationwide multicenter in Korea. Infect Chemoter. 2012. 44:282–288.

5. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrel TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group. National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis. 2008. 46:1813–1821.

6. Bergeron A, Porcher R, Sulahian A, de Bazelaire C, Chagnon K, Raffoux E, Vekhoff A, Cornet M, Isnard F, Brethon B, Lacroix C, Poirot JL, Bouges C, Derouin F, Tazi A, Ribaud P. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood. 2012. 119:1831–1837.

7. Herbrecht R, Denning DW, Patterson TF, Bennet JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002. 347:408–415.

8. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008. 46:327–360.

9. Choi SM, Park SH, Lee DG, Choi JH, Yoo JH, Min WS, Shin WS, Kim CC. Efficacy and safety profile of caspofungin as a salvage therapy for invasive fungal infections in Korean patients with hematologic diseases. Infect Chemother. 2005. 37:247–254.

10. Kwon JC, Kim SH, Choi SM, Choi JK, Lee DG, Park SH, Choi JH, Yoo JH, Shin WS. Efficacy and safety profile of voriconazole as salvage therapy for invasive aspergillosis with hematologic diseases in Korea. Infect Chemother. 2010. 42:17–22.

11. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007. 44:531–540.